【北京，中国】——精准医疗AI算法领域的先驱者Zephyr AI近日宣布，成功完成了一轮1.11亿美元的A轮融资，彰显了资本市场对其创新技术的高度认可。本轮融资由知名投资机构Revolution Growth领投，同时获得了医药巨头礼来公司、社会企业家Jeff Skoll以及EPIQ Capital Group等重量级投资者的共同支持。
Zephyr AI，一家专注于开发快速且可解释的人工智能解决方案的医疗技术公司，通过其独特技术在精准医疗领域开辟了新的道路。公司致力于利用AI提升医疗诊断和治疗的精确度，为患者提供更个性化、更有效的医疗服务。此次巨额融资将加速Zephyr AI在产品研发、市场拓展以及人才引进等方面的战略布局，进一步推动精准医疗领域的科技进步。
Revolution Growth的代表表示，他们对Zephyr AI的潜力充满信心，认为其AI技术有望重塑医疗行业，提高诊疗效率，降低医疗成本。礼来公司也对此次投资表达了期待，期待与Zephyr AI在药物研发和临床试验等方面展开深度合作，共同推动医疗科技创新。
Zephyr AI的创始人兼首席执行官在声明中强调，这笔资金将用于强化公司的技术领先地位，同时加强与全球医疗伙伴的合作，以实现更广泛的医疗普惠。他指出，可解释的人工智能是精准医疗的关键，Zephyr AI的目标是让AI成为医疗决策的强大辅助工具。
随着医疗AI领域的持续升温，Zephyr AI的这一轮融资无疑为行业发展注入了新的活力。该公司未来的表现，无疑将备受业界关注。
英语如下：
**News Title:** “Zephyr AI, a Precision Medicine Startup, Secures $110M in Series A Funding, Pioneering a New Era in AI-Driven Healthcare”
**Keywords:** Zephyr AI, Precision Medicine, Series A Funding
**News Content:**
**Beijing, China** — Zephyr AI, a pioneer in AI algorithms for precision medicine, recently announced the successful completion of a $110 million Series A funding round, demonstrating strong endorsement from the capital market for its innovative technology. The round was led by prominent investment firm Revolution Growth, with participation from pharmaceutical giant Eli Lilly, social entrepreneur Jeff Skoll, and EPIQ Capital Group, among other notable investors.
Zephyr AI, a medical technology company focused on developing fast and explainable AI solutions, has paved a new path in the precision medicine landscape. The company aims to enhance the accuracy of medical diagnosis and treatment through AI, enabling more personalized and effective healthcare services for patients. This substantial funding will expedite Zephyr AI’s strategic expansion in product development, market growth, and talent acquisition, further propelling advancements in precision medicine.
Representatives from Revolution Growth expressed confidence in Zephyr AI’s potential, believing its AI technology has the potential to reshape the healthcare industry, improving diagnostic efficiency and reducing costs. Eli Lilly also expressed anticipation for the investment, looking forward to collaborating with Zephyr AI on drug development and clinical trials to drive medical innovation.
Zephyr AI’s founder and CEO stated that the funds will be utilized to solidify the company’s technological leadership and strengthen partnerships with global healthcare entities, striving for broader access to healthcare. He emphasized that explainable AI is crucial for precision medicine, with Zephyr AI’s goal being to make AI a powerful辅助 tool in medical decision-making.
As the medical AI sector continues to heat up, Zephyr AI’s funding round injects fresh vitality into the industry. The company’s future performance is now under heightened industry scrutiny.
【来源】https://www.businesswire.com/news/home/20240312475536/en/Zephyr-AI-Raises-111-Million-in-Series-A-Financing
Views: 1